193. プラダー・ウィリ症候群 Prader-Willi syndrome Clinical trials / Disease details

臨床試験数 : 111 / 薬物数 : 120 - (DrugBank : 30) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 103

diseases per page:

Showing 1 to 10 of 111 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03831425 (ClinicalTrials.gov)	May 1, 2022	22/1/2019	Mitochondrial Complex I Dysfunction in PWS	Mitochondrial Complex I Dysfunction in Prader Willi Syndrome: A New Therapeutic Target	Prader-Willi Syndrome	Dietary Supplement: Coenzyme Q10;Other: Placebo	The Hospital for Sick Children	Foundation for Prader-Willi Research	Recruiting	13 Years	18 Years	All	14	Phase 2	Canada
2	NCT05153434 (ClinicalTrials.gov)	March 24, 2022	30/11/2021	A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome	A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ARD-101 in Patients W ...	Prader-Willi Syndrome	Drug: ARD-101	Aardvark Therapeutics, Inc.	Children's Hospital Colorado	Recruiting	17 Years	65 Years	All	12	Phase 2	United States
3	NCT05098509 (ClinicalTrials.gov)	March 15, 2022	22/9/2021	A Phase 2/3 Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader-Wi ...	A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution ...	Prader-Willi Syndrome	Drug: RAD011;Drug: Placebo	Radius Pharmaceuticals, Inc.	NULL	Not yet recruiting	8 Years	65 Years	All	220	Phase 2/Phase 3	United States
4	EUCTR2021-000127-12-SE (EUCTR)	03/01/2022	08/11/2021	A 16-week phase 2b, double-blind, placebo-controlled, Multi center, dose finding safety and efficacy ...	A Phase 2b, Double-blind, Randomized, Placebo-controlled, Multi center, 16-week Dose finding, Safety ...	Prader-Willi Syndrome MedDRA version: 20.0;Level: PT;Classification code 10036476;Term: Prader-Willi ...	Product Name: Tesomet INN or Proposed INN: Tesofensine Other descriptive name: TESOFENSINE CITRATE INN o ...	Saniona A/S	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	120	Phase 2	France;United States;Spain;Belgium;Ireland;Australia;United Kingdom;New Zealand;Italy;Sweden
5	NCT05198362 (ClinicalTrials.gov)	December 28, 2021	5/1/2022	Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome	A Phase 2b, Double-blind, Randomized, Placebo-controlled, Multi-center, 16-week Dose Finding, Safety ...	Prader-Willi Syndrome	Other: Placebo;Drug: Tesomet	Saniona	NULL	Recruiting	13 Years	65 Years	All	120	Phase 2	United States
6	NCT05032326 (ClinicalTrials.gov)	September 7, 2021	24/6/2021	Long-term Interventional Follow-up Study of Children With Prader-Willi SyndromeIncluded in the OTBB3 ...	Long-term Interventional Follow-up Study up to 4 Years of Age of Children With Prader-Willi Syndrome ...	Prader-Willi Syndrome	Drug: Follow-up study of the treated cohort;Other: Follow-up study of the untreated cohort	University Hospital, Toulouse	NULL	Recruiting	12 Months	36 Months	All	80	Phase 3	France
7	EUCTR2019-002385-12-NL (EUCTR)	26/08/2021	08/09/2020	Oxytocin treatment in neonates and infants aged from 0 to 3 months with prader-willi syndrome	Oxytocin treatment in neonates and infants aged from 0 to 3 months with prader-willi syndrome: a stu ...	Prader-Willi Syndrom;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Product Name: Oxytocin INN or Proposed INN: OXYTOCIN Other descriptive name: OXYTOCIN	University Hospital of Toulouse	NULL	Not Recruiting			Female: yes Male: yes	48	Phase 3	France;Belgium;Germany;Netherlands
8	EUCTR2019-002385-12-DE (EUCTR)	07/07/2021	21/04/2021	OXYTOCIN TREATMENT IN NEONATES AND INFANTS AGED FROM 0 TO 3 MONTHS WITH PRADER-WILLI SYNDROME	OXYTOCIN TREATMENT IN NEONATES AND INFANTS AGED FROM 0 TO 3 MONTHS WITH PRADER-WILLI SYNDROME: A STU ...	Prader-Willi Syndrome;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Product Name: Oxytocin INN or Proposed INN: OXYTOCIN Other descriptive name: OXYTOCIN	University Hospital of Toulouse	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	48	Phase 3	France;Belgium;Netherlands;Germany
9	ChiCTR2100046551	2021-05-18	2021-05-21	Multimodal magnetic resonance imaging changes in Prader-Willi syndromebefore and after growth hormon ...	Application of multimodal magnetic resonance imaging in pre - and post-treatment evaluation of recom ...	Prader-Willi sydrome	Prader-Willi sydrome group treated with rhGH:Treat with rhGH;Prader-Willi sydrome group treated with ...	Cai Jinhua	NULL	Recruiting	0	16	Both	Prader-Willi sydrome group treated with rhGH:40;Prader-Willi sydrome group treated without rhGH:40;Normal development group:40;	N/A	China
10	EUCTR2019-000735-61-NL (EUCTR)	06/04/2021	04/08/2020	Treatment with N-acetylcysteine for skin picking in children and young adults with PWS	N- acetylcysteine treatment for skin picking in children and young adults with PWS: a randomized, co ...	Prader-Willi syndrome MedDRA version: 20.0;Level: PT;Classification code 10036476;Term: Prader-Willi ...	Trade Name: Fluimucil (acetylcysteine) Product Name: Fluimucil Product Code: R05CB01	Dutch Growth Research Foundation	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	35	Phase 2;Phase 3	Netherlands

First Previous1 2 3 4 5…12Next Last